Home Pharmaceuticals Heparin Market Size & Share Analysis Report | By 2033

Heparin Market Size, Share & Trends Analysis Report By Product  (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-low Molecular Weight Heparin (ULMWH)), By Application (Venous Thromboembolism, Coronary Artery Disease, Atrial Fibrillation, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRPH2215DR
Last Updated : Feb 11, 2025
Author : Straits Research
Starting From
USD 2300
Buy Now

Heparin Market Size

The global heparin market size was valued at USD 7.77 billion in 2024 and is projected to grow from USD 7.98 billion in 2025 to USD 9.66 billion by 2033, exhibiting a CAGR of 2.4% during the forecast period (2025-2033).

Heparin is an anticoagulant (blood thinner) medication used to prevent and treat blood clots. It works by inhibiting clot formation in the blood, reducing the risk of conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. It is administered through injection, either intravenously or subcutaneously, and is commonly used during surgeries, dialysis, and in patients with clotting disorders. There are two main types—unfractionated heparin (UFH) and low molecular weight heparin (LMWH)—each with specific clinical applications. It plays a vital role in preventing life-threatening thrombotic events.

The global heparin market is experiencing substantial growth, driven by increasing surgical procedures, the rising prevalence of cardiovascular diseases, and the growing incidence of thromboembolic disorders such as DVT and PE. Advancements in low molecular weight heparins (LMWH) enhance treatment efficacy and patient outcomes, further boosting the market. The trend toward personalized medicine is creating opportunities for developing customized anticoagulant therapies. Pharmaceutical companies are investing in research to establish heparin-based treatments tailored to individual patient needs, minimizing adverse reactions and optimizing outcomes. Additionally, new product launches and ongoing clinical trials will likely introduce improved formulations, further boosting market growth.

The below graph shows the incidence rate of deep vein thrombosis from 2017 to 2023.

Source: Straits Research, National Library of Medicine

According to the data above, a higher incidence of cases was reported due to upper extremity deep vein thrombosis (UE DVT). This rise can be attributed to the increased use of central venous catheters and prolonged hospital stays. The growing adoption of heparin in outpatient care, veterinary medicine, and emerging applications in regenerative medicine is further expanding market opportunities. Regulatory approvals and government initiatives to strengthen the anticoagulant supply chain also expand the market. Ongoing innovations and strategic collaborations are further boosting the global heparin market growth.

Heparin Market Trends

Growing use in cancer treatment

The growing use of heparin in cancer treatment boosts the growth. Low molecular weight heparins (LMWHs) effectively manage cancer-related hemostatic disorders, as they offer a more predictable anticoagulant response.

  • For instance, in October 2023, an article in the National Library of Medicine highlighted using low molecular weight heparin (LMWH) for treating cancer-associated venous thromboembolism (VTE). It reduces the coagulation and bleeding in the cancer patients.

This trend highlights the continued demand for heparin-based therapies in oncology care, boosting growth.

Rising demand for low molecular weight heparin (LMWH)

The rising demand for low molecular weight heparin (LMWH) is propelled by its enhanced efficacy, predictable pharmacokinetics, lower risk of complications, and ease of use. LMWH advantages over unfractionated heparin, including convenient subcutaneous administration and longer half-life, make it increasingly preferred for treating conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE).

  • For instance, in September 2024, a study published by the National Library of Medicine highlighted the increasing preference for LMWH in patients undergoing noncardiac surgery after percutaneous coronary intervention (PCI)

This trend highlights the rising demand for LMWH due to its predictable pharmacokinetics, lower risk of complications, and convenience over unfractionated heparin.


Heparin Market Growth Factors

Rising prevalence of cardiovascular diseases & thrombosis

The rising prevalence of cardiovascular diseases (CVD) and thrombosis is a major driver for the market, with conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF) fuelling demand. The increasing incidence of these disorders boosts the need for anticoagulants like heparin, which is essential in preventing and treating thrombotic events, thereby driving global heparin market growth.

  • For instance, in 2022, according to a study published by the National Library of Medicine, cardiovascular diseases (CVD) caused an estimated 19.8 million deaths worldwide, highlighting the urgent need for effective treatments such as heparin to manage thrombosis and reduce mortality associated with CVD-related complications.

This highlights the growing need for effective anticoagulants such as heparin to prevent and manage thrombotic events, which boosts the market.

Increase in surgical interventions

The increasing number of surgical interventions globally drives demand for anticoagulants such as heparin. Heparin is critical during cardiac, orthopedic, and dialysis surgeries to prevent blood clots, driving market growth.

  • For instance, in July 2023, an article published in the National Library of Medicine highlighted the increasing use of heparin in various surgical interventions, such as cardiac surgery, extracorporeal circulation, and dialysis procedures, to prevent excessive coagulation.

The growing number of complex and high-risk surgeries highlights the increasing dependence on heparin to regulate coagulation and enhance patient outcomes during these procedures.

Market Restraining Factors

Supply chain disruptions

Supply chain disruptions pose a significant challenge to the market. Factors such as the limited availability of raw materials, reliance on animal sources (primarily porcine intestines), transportation delays, and geopolitical tensions severely affect production and distribution. These issues lead to shortages, increased costs, and limited access to heparin, a critical anticoagulant for preventing and treating blood clots in emergency and surgical settings.

  • For example, during the COVID-19 pandemic, global heparin supply chains faced severe disruptions due to restrictions on transportation, reduced workforce availability, and heightened demand for anticoagulants in treating COVID-19 complications.

This caused regional shortages and substantial price increases, highlighting the supply chain's vulnerability. The ongoing geopolitical tensions between key exporting and importing countries have added to the uncertainty in raw material availability and pricing.

Key Market Opportunities

Advancements in heparin purification

Advancements in heparin purification processes and alternative sourcing methods present promising growth opportunities. Recent purification technology innovations improve heparin's safety and efficacy while reducing contamination risks. Additionally, exploring alternative sources like bovine-derived heparin can help mitigate supply chain challenges associated with porcine-derived heparin.

  • For instance, in May 2024, a study published in the National Library of Medicine highlighted advancements in heparin purification, demonstrating that bovine intestinal heparin could be a viable source for enoxaparin. The bovine-derived enoxaparin exhibited anticoagulant properties comparable to the porcine-derived standard through a single purification step, showcasing promising improvements in production methods.

Such advancements in purification and exploring alternative sources like bovine-derived heparin are essential in meeting the growing demand for safe and effective anticoagulant treatments.

Study Period 2021-2033 CAGR 2.4%
Historical Period 2021-2023 Forecast Period 2025-2033
Base Year 2024 Base Year Market Size USD 7.77 billion
Forecast Year 2033 Forecast Year Market Size USD 9.66 billion
Largest Market Europe Fastest Growing Market Asia Pacific
Talk to us
If you have a specific query, feel free to ask our experts.

Regional Insights

North America: Dominant region with 39.4% market share

North America is leading in the global heparin market due to high healthcare spending and the widespread use in critical care, surgeries, and cardiovascular treatments. The region also benefits from a robust regulatory framework, a strong demand for innovative therapies, and a high prevalence of conditions such as coronary artery disease and deep vein thrombosis, which require adequate anticoagulation.

Asia Pacific: Fastest growing region with the highest market CAGR

The Asia-Pacific region is expected to register the fastest CAGR during the forecast period. This is attributed to increasing healthcare investments, rising prevalence of cardiovascular diseases and thromboembolic disorders, and growing awareness of anticoagulant therapies. Additionally, expanding healthcare infrastructure, a large patient population and the increasing adoption of advanced medical treatments are contributing to the region's rapid growth of the market.

Country Insights

The market is experiencing dynamic growth and diversification across the globe, with each country contributing uniquely to advancing this transformative field.

  • S.-The U.S. is a leader in the market due to the innovative product launch and approvals. For instance, in February 2022, Techdow USA announced the launch of heparin sodium injection in the U.S., expanding its product portfolio and pipeline to meet better the needs of customers and patients in the country.
  • Spain–In Spain, the market is driven by key players' expansion of new facilities. In June 2024, ROVI expanded its Spain plant with a new sodium heparin production line. This increase in capacity for low-molecular-weight heparins aims to meet growing global demand. The facility is expected to produce up to 88 million syringes annually, strengthening the supply chain of crucial anticoagulants.
  • China-The China market is driven by the rising prevalence of cardiovascular diseases, increasing demand for anticoagulants in surgeries, advancements in formulations, and the growing use of heparin-coated medical devices in the country.
  • France-In France, the market growth is driven by the increasing prevalence of cardiovascular diseases, rising surgical procedures, and the growing demand for effective anticoagulants. Additionally, advancements in healthcare infrastructure, stronger regulatory frameworks, and the adoption of low-molecular-weight heparins contribute to the market's expansion.
  • India–India is experiencing rapid growth in the market, driven by the launch and approval of innovative products in the country by government organizations. For instance, in March 2022, Shenzhen Hepalink Pharmaceutical Group announced the approval of its Heparin Sodium Active Pharmaceutical Ingredient (API) and Enoxaparin Sodium API by the Central Drugs Standard Control Organisation (CDSCO) in India. This approval is part of Hepalink's expansion into the Indian market.
  • Malaysia-The Malaysian market is driven by strategic initiatives and collaboration between key players. For instance, in July 2022, Pharmaniaga collaborated with Suzhou Ronnsi Pharma to commercialize Malaysia’s first halal blood clot thinner. This partnership aims to meet the increasing demand for halal-certified pharmaceuticals in Malaysia.
  • Japan-Japan is witnessing significant growth in its market, driven by advanced healthcare infrastructure and the high demand for effective anticoagulants such as heparin for treating thromboembolic disorders, further driving market growth. Additionally, regulatory support for the use of low-molecular-weight heparins (LMWH) and the growing focus on improving patient outcomes drives market growth in the country.
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Segmentation Analysis

The global heparin market is segmented based on product type, source, route of administration, application, and end-user.

By Product Type

Low molecular weight heparin (LMWH) dominates the global market due to its enhanced efficacy, predictable pharmacokinetics, and lower risk of complications compared to UFH. LMWH offers key advantages such as convenient subcutaneous administration, longer half-life, and reduced monitoring requirements. These characteristics make LMWH the preferred choice for conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as during pregnancy, to prevent clotting complications.

By Source

Porcine-derived heparin remains the most widely used form in the global market due to its high efficacy, availability, and cost-effectiveness. Its structural similarity to human heparin and extensive clinical research make it the standard choice for anticoagulant therapy. However, growing concerns over supply disruptions have spurred interest in alternative sources like bovine-derived and synthetic heparin.

By Route of Administration

Parenteral administration, which includes intravenous and subcutaneous injections, is the most common route for delivery due to its rapid onset of action and high bioavailability. Intravenous administration is preferred for acute conditions requiring immediate anticoagulation, while subcutaneous administration is widely used for long-term management of thromboembolic disorders. The precise dosing and immediate therapeutic effects make parenteral administration critical in surgeries and critical care settings.

By Application

The coronary artery disease (CAD) segment holds the largest share of the market due to the high demand for anticoagulation during cardiac interventions, including coronary artery bypass grafting (CABG), percutaneous coronary interventions (PCI), and angioplasty procedures. Heparin is essential for preventing thrombosis and ensuring proper blood flow during these high-risk cardiac procedures, making it a cornerstone therapy in cardiology.

By End-User

Hospitals and clinics dominate the global market as they handle a high volume of critical care cases, surgeries, and treatments for thromboembolic disorders. The availability of trained medical professionals and specialized infrastructure ensures the proper administration and monitoring, making hospitals and clinics the primary consumers of anticoagulant therapies. Increased focus on improving patient outcomes in critical care further reinforces their market dominance.

Market Size By Product Type

Market Size By Product Type
Unfractionated Heparin (UFH) Low Molecular Weight Heparin (LMWH) Ultra-Low Molecular Weight Heparin (ULMWH)

List of key players in Heparin Market

  1. Intelicure Lifesciences
  2. Montage Laboratories Pvt. Ltd.
  3. Reddy’s Laboratories, Ltd.
  4. Pfizer Inc.
  5. Laboratorios Farmaceuticos ROVI SA
  6. Braun Medical, Inc.
  7. Flagship
  8. Aspen Holdings
  9. Baxter
  10. Bioiberica S.A.U.
  11. Sanofi
  12. Bacto Chem Laboratories
  13. Opocrin S.p.A.
  14. Biological E Limited
  15. Hepalink Group
Heparin Market Share of Key Players

Company Market Share

Key players in the industry are focused on adopting key business strategies, such as strategic collaborations, product approvals, acquisitions, and product launches, to gain a strong foothold in the market.

Flagship: An emerging player in the Heparin market

Flagship is a pharmaceutical company specializing in manufacturing and supplying high-quality injectable formulations. They offer a range of anticoagulant products, including heparin injections, used in treating and preventing thromboembolic conditions.

Recent developments by Flagship:

  • Flagship manufactures heparin injections in various strengths, including 1000 IU/ml and 5000 IU/ml, to meet diverse medical needs. The company prioritizes quality and innovation, following stringent manufacturing standards to ensure the safety and efficacy of its heparin product

Recent Developments

  • February 2024- Braun Medical Inc. introduced a new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL). This addition expands their portfolio of heparin premixed bags, aiming to enhance patient safety and streamline hospital pharmacy operations.
  • May 2024-Research published by Rensselaer Polytechnic Institute highlighted significant progress in heparin purification processes. The study demonstrated that bovine intestinal heparin could serve as a viable source for enoxaparin, offering anticoagulant properties comparable to traditional porcine-derived heparin. This advancement could address supply chain challenges and reduce dependence on animal sources.

Analyst Opinion

As per our analyst, the global heparin industry is set for sustained growth, driven by the increasing prevalence of cardiovascular diseases, deep vein thrombosis, and pulmonary embolism. Advancements in synthetic and low-molecular-weight heparins and regulatory approvals for innovative anticoagulants are fuelling market expansion. Strategic collaborations and manufacturing expansions, especially in North America and Asia-Pacific, support stability and propel market growth. Additionally, the rising adoption of in surgical procedures and veterinary medicine further drives the market growth.


Heparin Market Segmentations

By Product Type (2021-2033)

  • Unfractionated Heparin (UFH)
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)

By Source (2021-2033)

  • Porcine
  • Bovine
  • Others

By Route of Administration (2021-2033)

  • Parenteral Administration
  • Oral Administration

By Application (2021-2033)

  • Coronary Artery Disease
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Kidney Dialysis
  • Others

By End-User (2021-2033)

  • Hospitals and Clinics
  • Ambulatory Surgery Centre
  • Others

Frequently Asked Questions (FAQs)

How Big is Heparin Market?
Straits Research Predicts that the global heparin market size was valued at USD 7.77 billion in 2024 and is projected to grow from USD 7.98 billion in 2025 to USD 9.66 billion by 2033
Some of the top prominent players in Heparin Market are, Baxter International Inc., B. Braun Holding GmbH & Co. KG, Dr Reddy's Laboratories Ltd., Fresenius SE & Co KGaA, Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Leo Pharma A/S, Pfizer Inc., Sanofi SA., Teva Pharmaceuticals, Viatris Inc., etc.
Europe has been dominating the Heparin Market, accounting for the largest share of the market.
The Asia Pacific region is projected to exhibit the highest rate of growth in the Heparin Market.
The global Heparin Market report is segmented as follows: By Product, By Application, By Distribution Channel


We are featured on :